LEF1 EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A MARKER FOR DIAGNOSIS AND SURVIVAL PREDICTION

NCT ID: NCT07313982

Last Updated: 2026-01-02

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 350 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-12-31
• Study Completion Date: 2027-08-31

Brief Summary

Chronic lymphocytic leukemia (CLL) is a highly heterogeneous B-cell hematological malignancy characterized by clonal expansion and accumulation of morphologically mature B-lymphocytes with a peculiar immunophenotype in peripheral blood, bone marrow, and secondary lymphoid tissues. Diagnosis is usually possible by flow cytometry, while lymph node and/or bone marrow biopsy may be helpful if immunophenotyping is inconclusive. A better understanding of pathogenesis has, recently, allowed the identification of new markers, improving patient stratification, implementing the therapeutic armamentarium with new agents targeting key intracellular signaling pathways. The canonical Wnt/β-catenin pathway is well recognized and known to drive malignant transformation of several cancer types including B-CLL. High expression of WNT3 and its transcription factor LEF1 in CLL considered as one of the strongest facts supporting the role of this pathway in CLL.

The evaluation of LEF-1 expression by immunohistochemistry in the diagnostic setting is still limited and a substantial number of CLL patients with negative LEF-1 expression has been reported. This is a study of LEF-1 expression to test the utility of using it for optimizing the B-CLL diagnosis and correlate it with the immunohistochemical, clinical and molecular data and compare LEF-1 negative and positive cases to identify a possible LEF-1 expression related signature that could be useful in differential diagnosis, in prognostic stratification and possibility of using targeted drugs

Detailed Description

Small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) is the most common chronic leukemia in adults in Western countries. SLL/CLL is classified as a chronic lymphoproliferative disorder within the category of mature B-cell neoplasms according to the World Health Organization (WHO) classification, and is characterized by the relentless accumulation of mature B lymphocytes displaying a distinctive immunophenotype. The disease may involve peripheral blood, bone marrow, lymph nodes, and the spleen. The median age at diagnosis is approximately 70 years, although about 10% of cases occur in young adults, and males are affected more frequently than females. In Western countries, the incidence is 2-6 cases per 100,000 inhabitants per year, increasing with age.¹ The clinical course of CLL is highly heterogeneous: most patients have an indolent course requiring no therapy or delayed treatment with prolonged survival, whereas others present with an aggressive disease requiring early treatment and experiencing frequent relapses.

SLL/CLL is generally diagnosed during routine blood testing in asymptomatic patients who exhibit absolute lymphocytosis, often with Gumprecht shadows visible on peripheral blood smears (representing fragile lymphocytes disrupted during slide preparation). The diagnosis of SLL/CLL is based on the presence of ≥5,000/µl clonal B lymphocytes in peripheral blood, which on flow cytometry are CD19+, CD5+, CD23+, CD200+, with dim CD20 expression, weak CD22 and/or CD79b, and weak surface immunoglobulin expression with light-chain restriction. Diagnosis is usually achievable through immunophenotyping of peripheral blood, whereas lymph node biopsy and/or bone marrow biopsy may be useful when immunophenotyping is inconclusive.

In the diagnostic work-up of SLL/CLL, CD5, CD19, CD20, CD23, and surface or cytoplasmic kappa/lambda light chains are considered essential markers, while CD10, CD43, CD79b, CD81, CD200, and ROR1 serve as additional antigens useful for differential diagnosis among small B-cell lymphomas/leukemias. Beyond assessing del(11q), del(13q), del(17p), and trisomy 12, TP53 mutational analysis and evaluation of somatic hypermutation (SHM) of the immunoglobulin heavy-chain variable region (IGHV) are essential for comprehensive prognostic assessment in SLL/CLL. IGHV mutational status and TP53 status are included in the CLL International Prognostic Index (CLL-IPI), together with age, clinical stage, and β2-microglobulin levels. Assessment of karyotypic complexity and the mutational status of BTK, PLCG2, and BCL2 remain desirable additional investigations within a targeted-therapy approach.

In recent years, improved understanding of SLL/CLL pathogenesis has clarified preneoplastic conditions (e.g., monoclonal B-cell lymphocytosis), enabled identification of novel diagnostic, prognostic, and predictive markers, refined patient stratification, and expanded the therapeutic armamentarium with new agents targeting key intracellular signaling pathways. Among these, several studies have demonstrated dysregulation of the WNT/β-catenin pathway in SLL/CLL. The final mediator of this pathway is LEF-1 (lymphoid enhancer-binding factor 1), a key transcription factor regulating cell proliferation and survival and playing a fundamental role in lymphopoiesis. LEF-1 is normally expressed in a subset of T cells and in B-cell precursors but is silenced in mature B cells; however, gene expression profiling studies have shown overexpression of LEF-1 in SLL/CLL compared with normal B cells. This expression is detectable by immunohistochemistry in tissue samples, where its presence has been confirmed. Nonetheless, although LEF-1 expression has demonstrated usefulness in distinguishing SLL/CLL from other indolent B-cell lymphomas, its diagnostic application remains limited. Moreover, a subset of CLL patients does not express LEF-1, and the characteristics of these patients have not yet been investigated.

The aim of this study, with an anticipated enrollment of up to 350 patients with a confirmed diagnosis of SLL/CLL and available molecular data at diagnosis, is to re-evaluate immunohistochemical expression on biopsy specimens (most commonly bone-marrow biopsies) to:

1. confirm actual LEF-1 expression positivity, and

2. statistically assess potential clinical correlations between LEF-1-positive and LEF-1-negative subsets, in an effort to identify possible diagnostic, prognostic, or therapeutic implications.

The study is observational, multicenter, national, retrospective/ Prospective cohort.

Conditions

Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Eligibility Criteria

Inclusion Criteria

• Patients with a confirmed diagnosis of SLL/CLL - B
• Males and females, adults at diagnosis
• Patients with available tissue (lymph node, extralymph node, or bone marrow) on which immunohistochemical analysis including LEF-1 has been performed and who have already submitted mutational and/or cytogenetic analysis data.

Exclusion Criteria

• - Patients with LEF1-positive indolent B-cell lymphomas not supported by a genetic evaluation with SSL/CLL.
• CLL cases for which a biopsy is not available

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER

Sponsor Role: lead

Responsible Party

Elena Sabattini

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Irccs Azienda Ospedaliero-Universitaria Di Bologna

Bologna, BOLOGNA, Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

ELENA SABATTINI, MD

Role: CONTACT

elena.sabattini@aosp.bo.it

+390512144562

GIOVANNA MOTTA, BS

Role: CONTACT

giovanna.motta@aosp.bo.it

051214 3045

Facility Contacts

ELENA SABATTINI, MD

Role: primary

elena.sabattini@aosp.bo.it

+390512144562

GIOVANNA MOTTA, BS

Role: backup

giovanna.motta@aosp.bo.it

0512143045

Other Identifiers

LLC/LEF1 2024

Identifier Type: -

Identifier Source: org_study_id